A phase I/II trial at the MD Anderson Cancer Center assessed the therapeutic potential of HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood in relapsed or refractory CD19-positive cancers, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [138]. Here, CD19 is linked to non-Hodgkin lymphoma.